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Summary FK 506 was given for immunosuppression 
in 14 liver recipients. The drug was used in 
the first 10 cases because the recipients under conventional 
immunosuppression had rejection, nephrotoxicity, or both. 
This salvage therapy was successful in 7 of the 10 attempts. 2 
of the 10 patients in the original salvage group as well as 4 
new patients underwent fresh orthotopic liver trans-
plantation under FK 506 plus low-dose steroids from the 
outset. None of these 6 patients had rejection although 1 
with preexisting cor pulmonale and coronary atherosclerosis 
died of a myocardial infarction. In addition, 2 of the 14 liver 
recipients were given cadaveric kidneys, either from the 
same donor or from a different donor, and a third was given a 
pancreas as well as a kidney from the liver donor. There were 
no rejections of the kidney and pancreas grafts, and serious 
side-effects were not encountered. 
Introduction 
CYCLOSPORIN has been an essential factor in the 
expansion of transplantation services during the past 
decade.' However, its nephrotoxicity and other limitations 
have stimulated a continuing search for alternative agents. 
We report here the first clinical trials in liver recipients of a 
new drug that is not related chemically to cyclosporin or to 
other standard immunosuppressants. FK 506, a macrolide 
produced by Streptomyces tsukuhaensis, was discovered in 
1984 in Japan during a search for new immunosuppressive 
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and cancer chemotherapeutic agents. It was shown to be 
immunosuppressive in vitro by Kino et al2 and in rats by 
Ochiai et al' and by numerous others (see ref 4) throughout 
1987. A major divergence of opinion quickly surfaced about 
the potential clinical value of the agent. From our studies of 
heart, kidney, or liver transplantation in rats,S dogs,6--8 and 
subhuman primates,8,9 we judged it worthy of a clinical trial. 
In contrast, workers at Cambridge University reported 
unacceptable toxicity including widespread arteritis, 10 
However, we8 and Ochiai et al" have shown such vascular 
lesions to be present in non-immunosuppressed dogs after 
whole organ transplantation and in dogs treated with other 
agents including cyclosporin. Arteritis has not been a feature 
in baboons treated with FK 5069 or in formal toxicology 
studies.8 When examining its effects in man we did not feel 
justified in conducting potentially dangerous pharmaco-
kinetic studies in normal volunteers, as is the usual practice 
in drug development. Instead the agent was given, in the 
first instance, to patients in desperate plight because their 
liver grafts were being rejected despite conventional 
immunosuppression. 
Later, it was combined with low doses of steroids as 
primary antirejection treatment for high-risk recipients of 
livers, kidneys, and in one case a pancreas. 
Methods 
Liver Graft Rescue 
The original hepatic diagnoses in these 10 patients were 
POSUlecrotic cirrhosis (6) and sclerosing cholangitis (4). 
Conventional treatment was deemed to have failed if there was acute 
or chronic graft rejection despite immunosuppression with 
cycJosporin and steroids with or without adjuvant antilymphocyte 
globulin (polycJonal or monoclonal) and/or azathioprine. In most 
patients, abnormal renal function had imposed limits on the amount 
of cycJosporin that could be given, Patient 3 had undergone a renal 
tranplantation in December, 1988, but this kidney showed 
end-stage chronic rejection on biopsy. The hepatic grafts that were 
undergoing rejection had been in place for 12 days to 61 years. 4 of 
the 10 patients had already undergone retransplantation one to four 
times, and the starting point for the FK 506 study was based on the 
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last graft. 9 of the 10 patients had abnormal tests of liver function 
and/or injury-jaundice in 7 (total bilirubin 37·6-359 ~ol/fF and 
raised serum aminotransferases and canalicular enzymes (alkaline 
phosphatase and/or gamma-glutamyl transferase) in 9. Patients 5 
and 10 were gravely ill with acute hepatic failure when FK 506 was 
started and they had already been listed with the national organ 
procurement network as candidates for emergency retrans-
plantation. The diagnosis and characteristics of rejectipn were 
established by liver biopsy in all 10 patients; duct injury and cellular 
infiltration were prominent features, vascular injury and fibrosis 
being less common. 
An additional patient who had undergone hepatic and renal 
transplantation in November, 1988, for polycystic liver and kidney 
disease was entered into the FK 506 rescue protocol on April 8, 
1989, but was withdrawn a few days later when the diagnosis was 
revised to acute B virus hepatitis. 
Fresh Liver Grafts 
Patients 2 and 9, whose livers could not be salvaged with KF 506, 
received new grafts (their sixth and second liver, respectively) under 
FK 506 and low-dose steroids. This sixth liver replacement in 
patient 2 was performed under emergency conditions when 
occlusion of the arterial conduit to graft number 5 led to septic 
hepatic gangrene of the hilum, gram-negative bacteraemia, and 
septic shock. Patient 9 was jaundiced but in good condition at the 
time of retransplantation. 
In addition, four primary liver transplantations were done under 
FK 506 and low-dose steroids. The first patient (no 11) was a 
hepatitis B virus carrier with postnecrotic cirrhosis, juvenile 
diabetes mellitus, and renal failure. He had such severe autonomic 
neuropathy that he could no longer eat. The next 3 patients had 
postnecrotic cirrhosis and pulmonary hypertension (case 12), 
cirrhosis plus multifocai nodular hyperplasia (case 13), and 
postnecrotic cirrhosis (case 14). Patient 12 had cor pulmonale, 
pulmonary artery pressure 80/40 mm Hg, systemic blood pressure 
120/60 mm Hg. 
Fresh Kidney Transplantation 
Liver recipients 1 and 3 had renal failure at the time of the switch 
from cyclosporin to FK 506. Twenty-seven and forty-seven days 
later, respectively, cadaver kidneys were transplanted under FK 
506 and low-dose steroids. In addition patient 11, who was anuric, 
received a kidney from his liver and pancreas donor. 
Pancreatico-duodeno-jejunal Transplantation 
In patient 11 the whole pancreas was placed intraperitoneally and 
arterialised with a Carrell patch on the right common iliac artery. An 
iliac vein graft from the cadaver donor was used to extend the portal 
vein for an outflow anastomosis to the anterior surface of the 
recipient right common iliac vein." The duodenum was closed in 
two layers and a 35 em segment of cadaveric jejunum was brought as 
a Brooke jejunostomy to the right lower quadrant for collection of 
pancreatic and exocrine secretions in an ileostomy bag.13 The 
pancreas graft, which was transplanted last of the three organs from 
the common donor, had a cold ischaemic period of 24 h compared 
with 12 h for the liver and 18 h for the kidney. 
Immunosuppression and Monitoring for Liver Salvage 
In the early cases we examined the effect of FK 506 on the 
pharmacokinetics of cyclosporin and observed increases in 
cyclosporin blood levels with associated nephrotoxicity. The results 
discouraged us from trying combined therapy. 
All patients received an initial intravenous bolus of 0·15 mg/kg 
FK 506 over 1 h. Plasma concentrations, measured by the two-step 
monoclonal enzyme immunoassay technique of Tamura et al,14 
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TABLE I-LIVER RECIPIENTS GIVEN RESCUE TREATMENT: 
FOLLOW-UP TO SEPT 14,1989 
I DateFK Serum creatinine 
506 E~M1!1F 
Age! Date of last started Fate of 
Patient sex liver graft (1989) liver graft Before After 
1 28/F June 29, '88* Feb 28 Salvaged 362 115 
2 381M Jan 1, '89' March 25 Replaced 195 195 
July 2t 
3 3O/F Nov 18, '87' April 4 Salvaged 477 Dialysis 
4 42/M April 30, '89 Feb 6 Salvaged 124 141 
5 38/F Feb 12,82 June 29 Salvaged 239 283 
6 47/M June 15, '86 Jan 7 Salvaged 248 239 
7 18/F July 18, '86* July 8 Salvaged 141 203 
8 63!F May 8, '89 July 30 Replacement ISO 141 
attempted 
Sept 5; 
diedt 
9 371M July 10, '89 Feb 8 Replaced 88 106 
Aug28t 
10 45/F July 29, '89 Aug 10 Salvaged 133 97 
*Third (case 1), fifth (case 2), and second (case 3 and 7) liver grafts. 
tGraft replaced because of arterial tbrombosis and septic hepatic gangrene 
(case 2) or because the small bileducts had already been destroyed (cases 8 and 
9). 
were highest (9·0-20'0 ng/ml) at the end of the 1 h infusion and fell 
exponentially thereafter (to 0·7-3·8 ng/ml after 12 h). When 
intravenous therapy was continued, 0·075 mg/kg was given every 
12 h until oral doses were started: at the lower intravenous doses, 
peaks ranged from 3·3 to 20 ng/l with 12 h troughs of 0·5 to 
5·Ong/ml. 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
TABLE II-LiVER HISTOLOGY BEFORE AND AFTER 
IN SAL V AGE GROUP 
Ponal Duct Duct 
Day infiltrate damage loss Fibrosis Function 
Pre-FK 1+ 1+ 0 0 Good 
15 0 0 0 0 
69 0 0 0 0 
Pre-FK 1+ 1+ 0 0 Graft 
12 + 0 0 0 replaced 
34 0 0 0 0 
94 0 0 0 0 
Pre-FK 2+ 1+ 0 0 Good 
14 0 0 0 0 
31 0 0 0 0 
141 • 1+ + 0 0 
Pre-FK 3+ 2+ 0 2+ Good 
14 + + 0 2 
51 0 0 + + 
Pre-FK 1+ 3+ 0 0 Good 
12 + 2+ 0 + 
19 0 2+ 0 + 
66 0 2+ + + 
Pre-FK 1+ + + 0 Good 
18 0 + 0 0 
32 0 0 0 0 
Pre-FK 2 2+ + + Good 
16 1 1+ + + 
Pre-FK 2+ 2+ + + Graft 
7 1 2+ 1+ + replaced 
37 + 2+ 2+ + 
Pre-FK 3+ 2+ 0 + Graft 
20 1 3+ 2+ 1 replaced 
27 + 3+ 3+ 1 
Pre-FK 2+ 2+ 0 + Improved; 
13 + + 0 1+ bilirubin 
27 0 0 0 1+ now 73·5 
llllIoljl 
*Patient placed back on cyclosporin after 120 days because of shortage of 
intravenous FK 506. This last biopsy was 21 days later. Patient has persistent 
low-grade lobular hepatitis. 
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TABLE III-FRESH TRANSPLANTATIONS 
Date of 
Date fresh Organ Graft Total 
started transplan- trans- function bilirubin Creatinine 
Patient (1989) tation planted (Sept 10) E~ol/lF E~ol/lF 
1 Feb 28 March 27 Kidney Nonnal 5·1 106 
2 Match 25 July 2 6th liver Nonnal 10·2 195 
3 April 4 May 21 2nd kid- Removed 12·0 -
ney June 20 
9 Aug 2 Aug 28 2nd liver Nonnal 44·5 106 
11 Aug 17 Aug 17 Liver Normal 20·5 97 
.. Kidney Normal 
.. Pancreas Normal 
12 Aug 18 Aug 18 Liver Died 18·8 106 
Sept 1* 
13 Aug 24 Aug 24 Liver Normal 6·8 61 
14 Sept 3 Sept 3 Liver Normal 32·4 124 
-Myocardial infarcnon. 
TABLE IV-COMPLAINTS DURING TREATMENT WITH FKS06 
Route 
Symptom Intravenous Oral 
Nausea 7 2* 
Vomiting 6 2* 
Headache 4 0 
Burning feet 2 0 
Flushing 1 0 
-TranSient. 
Oral doses ofFK 506 were 0·15 mg/kg every 12 h or 24 h. The 
absorption curves with oral administration showed only minor 
increases from trough to peak levels in stable patients, the maximum 
rise being observed after about 2 h. 12 h or 24 h plasma trough levels 
that were seemingly therapeutic ranged from 0·2 to as high as 6 or 
7 ng/ml without a detectable association with toxicity. The oral 
doses were adjusted downward to provide trough levels of less than 
3ng/ml. 
Prednisone doses were left temporarily at their previous level if 
these were 20 mg/day or less, were reduced to 20 mg if they had been 
higher, and were subsequently reduced further. 
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Immunosuppression and Monitoring for Fresh 
Transplantations 
A first intravenous dose of 0·15 mg/kg FK 506 was given after 
revascularisation of the graft, followed by 0·075 mg/kg twice a day; 
we proceeded to oral therapy in the same way as with graft salvage. 
6 patients received 200 mg methylprednisolone at the time of 
operation, the dose being reduced in 40 mg decrements to 20 
mg/day. In 2 others the previous maintenance dose of intravenous 
or oral methylprcdinosolone was left unchanged at 20 mg/day. 
Results 
Tables I-III summarise patient details and results . 
Liver Graft Rescue 
Grafts saivaged.-All 10 patients had a sustained 
improvement in at least some liver functions. 7 of the 10 liver 
grafts are still in place and providing good to normal 
function after FK 506 treatment for one to more than six 
months. Only 1 of these 7 patients (case 10) has jaundice; her 
bilirubin has fallen from 301·0 to 73·5 1J1l101/1. The 
improvements in liver function were very prompt (fig 1). 
Objective evidence of benefit was obvious by the time the 
first liver biopsy specimens were obtained after the start of 
therapy (fig 2). Table II records all biopsy data. The classic 
findings of liver rejection were ameliorated or eliminated. 
The ability to halt the duct injury was particularly striking in 
those patients whose duct injury was not already irreparable. 
Graft losses.-Patient 9 had severe rejection with 
prominent duct injury and patient 8 had no identifiable 
ducts in her graft before beginning treatment. Although 
there was diminution of other histopathological evidence of 
rejection (table II), the ducts were not restored nor was 
jaundice relieved in those 2 patients. Retransplantation was 
successful in patient 9. Patient 8 died on the operating table 
during attempted retransplantation. Patient 1 had 
improvement of liver function and histopathological 
findings for almost three months until development of 
regional hepatic gangrene. The liver was replaced. The 
conduit used to rearterialise his fifth graft proved to have a 
None 42yr 
Weight 54·6 to 62.5 kg 
~ 5. 200 
co - fS~ RMi-~~~~ ______ gi~~~~~~~~==~~ [y(400to2000mglday} Au FK506 Pred(20mglday} FK506(20mglday} 
Pred OKT3 (days 9fo 22) (sporadic) [y (400to150mglday) Pred (20 to 10mglday) 
10 1S 20 25 30 t 3S ~o 50 60 70 
FK 506 
6·20.89 
Days from transplantation 
Fig 1-Use of FK for salvage in patient 4, whose liver biopsy appearances are shown in fig 2. 
Cy = cyclosporin; aza = azathioprine; pred = prednisolone. 
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Fig 2-Uver biopsy specimens. 
A, before FK 506. Note prominent portal inflammation. Liver damage 
persisted despite trcatmc·nt with OKT3. B, three wc"Cks after initiation ofthc 
FK 50b, infilrratc has disappc"dred and repair of previous damage is evid""t . 
tight stricture which was thought to have completely 
obstructed the blood flow. 
Renal ftmcticm .- The previously placed renal homograft 
in patient 3 went on to complete failure. Renal function in 
the other 9 patients remained almost unchanged (table I) . 
Several patients with preexisting hyperkalaemia remained 
hyperkalaemic and were successfully treated with 
fludrocortisone acetate. Patient I, in whom hyperkalaemia 
was regarded as life-threatening, was treated by renal 
transplantation. 7 of the patients had arterial hypertension 
requiring medication before FK 506 was started: in 5 all 
antihypertensive drugs could be stopped, in 1 medication 
was reduced from two drugs to one, and in d1e 7th the 
regimen was unchanged. 
Fresh Grafts 
Livers.-The two livers inserted at retransplantation 
(patients 2 and 9) functioned well from the outset with no 
clinical evidence of rejection in the II and 21 weeks of 
follow-up. Postoperative biopsy showed no evidence of 
rejection. Patient I already had poor renal function and this 
did not become worse, and patient 9 had normal renal 
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Fig ~rse of FK S06 with steroids in a diabetic recipient of liver, 
kidney, and pancreas. 
Lap = laparotomy for 1I liver laceration and severe haemorrhage caused by 
too low placemc"Ot of a chest C.1thctcr. 
function throughout (tables I and III). The four primary 
liver grafts (patients 11-14) also performed flawlessly (fig 3). 
Biopsy specimens after I and 2 weeks showed no evidence of 
rejection. The recipients had no evidence of nephrotoxicity 
(table III). Patient 12, who had severe pulmonary 
hypertension, recovered smoothly until day 14 when she 
complained of abdominal pain and tenderness. Laparotomy 
showed no abnormality but she had a fatal myocardial 
infarction under anaesthesia. At necropsy there was 
extensive atherosclerosis of the aorta, and the left anterior 
descending coronary artery was occluded by plaque. There 
were typical fmdings of cor pulmonale including 
biventricular hypertrophy. The liver graft was normal 
except for a light mononuclear infiltrate in some of the portal 
areas, wid1 scattered microabscesses and microgranulomas. 
Kidlleys.-The cadaveric renal transplants in liver 
patients I and II have functioned well for five and a half 
months and one month, respectively. Current senun 
creatinines are 106 and 97 Ilffiol/l (table III). These patients 
are normotensive without antihypertensive therapy. The 
cadaveric kidney transplanted to liver patient 3 passed 
through a 2-weck period of acute tubular necrosis before 
diuresis began. 30 days postoperatively, disruption of the 
end-to-side renal arterial anastomosis to the external iliac 
artery (because of a candida infection) necessitated graft 
nephrectomy and ligation of the iliac artery. The removed 
renal graft showed acute fibrin thrombi in some of the polar 
arterioles. These were attributed to seeding from the suture 
line infection. There was no evidence of cellular rejection or 
drug toxicity. Under inununosuppression with cyclosporin, 
a7..athioprine, and prednisone, the recipient of the other 
kidney from the same donor likewise had disruption of the 
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renal arterial suture line on the 11 th postoperative day and 
died. In our programme this complication arises in about 1 
in 1500 kidney transplantations, and in this instance was 
thought to have been caused by contamination from the 
shared donor. 
Pancreatico-duoderw-jejunal graft.-The patient is 
insulin-free one month postoperatively. Biopsy specimens 
were taken from the jejunostomy bud on postoperative days 
twelve and twenty-one and were histopathologically normal 
except for small foci of granulation tissue in the lamina 
propria. 
Side-effects 
The first intravenous doses of FK 506 caused headaches 
in 4 patients, nausea, vomiting, or anorexia in 7, and flushing 
or burning of the feet in 3 (table IV). The oral preparation 
was well tolerated, causing transient nausea or vomiting in 
only 2 patients. There were no correlation between 
symptoms and plasma concentrations of FK 506. 
Discussion 
The performance of FK 506, both for salvage and for 
primary immunosuppression in high-risk patients, was 
impressive. The drug was remarkably free from unwanted 
effects. One disadvantage of our study was the impossibility 
of ruling out nephrotoxicity, but the weight of evidence is 
that the drug is not nephrotoxic in therapeutic doses and that 
it does not cause hypertension. With other agents such as 
azathioprine and cyclosporin, a dose ceiling is imposed by 
specific toxicity (bone marrow depression and 
nephrotoxicity, respectively). A comparable toxicological 
"litmus paper" to guide dose standardisation has not been 
identified with FK 506 and the therapeutic window may 
well be wide. With oral therapy, the only complaints or 
findings were nausea and vomiting and these were transient. 
In many of the first investigations with FK 506, the 
possibility was entertained of combining small doses with 
agents such as cyclosporin, with which it is synergistic in 
vitr015,16 and in animals.5,6,8,l1 Our clinical experience so far 
has not encouraged such combination therapy. The FK 506 
may have increased the toxicity of cyclosporin, possibly by 
raising its blood concentration. FK 506 was so potent and 
free of side-effects that the simplest expedient was to use it 
alone. 
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PREVALENCE OF ANTIBODIES TO 
HEPATITIS C VIRUS IN SPANISH PATIENTS 
WI1H HEPATOCELLULAR CARCINOMA AND 
HEPATIC CIRRHOSIS 
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Summary The prevalence of antibodies against 
hepatitis C virus (HCV) was investigated in 
96 patients with hepatocellular carcinoma, 106 patients with 
liver cirrhosis without evidence of cancer, and 177 controls 
without liver disease. 75% of patients with hepatocellular 
carcinoma had HCV antibodies (anti-HCV), a significantly 
higher proportion than that observed in patients with 
cirrhosis (55'6%), or controls (7'3%). The prevalence of 
anti-HCV was significantly higher in patients with alcoholic 
cirrhosis and hepatocellular carcinoma (76%) than in 
patients with alcoholic cirrhosis alone (38'7%), whereas in 
patients with cryptogenic cirrhosis there was no significant 
difference between those with and without primary liver cell 
cancer (81'4% and 77'5%, respectively). These results 
indicate that HCV infection may have a role in the 
pathogenesis of hepatocellular carcinoma, even in patients 
with chronic liver disease apparently related to other agents 
such as alcohol, and that this recently identified hepatitis 
virus may be found in a large proportion of patients with 
cryptogenic cirrhosis. 
Introduction 
HEPATOCELLULAR carcinoma is a common neoplasm 
world wide/ and epidemiological surveys from different 
areas have shown a relation between this neoplasm and 
several factors, especially infection with hepatitis B virus 
(HEV).1 The oncogenic role of HEV in hepatocellular 
carcinoma is particularly important in countries with a high 
prevalence of HEV infection,t-3 whereas in low prevalence 
areas hepatocellular carcinoma is more commonly related to 
other factors, especially cirrhosis in patients who do not have 
hepatitis B surface antigen (HEsAg).4,s Whether cirrhosis 
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